Prior CAR T-cell therapy does not compromise the clinical efficacy of CD20 x CD3 bispecific antibodies in diffuse large B-cell lymphoma. In phase 2 trials, epcoritamab achieved a 36% complete remission rate in post-CAR T patients compared to 39% overall. Similarly, glofitumab demonstrated complete remission rates in patients with prior CAR T exposure comparable to those who were CAR T-naive, with durable remissions observed in both groups.
In the phase 3 EPCORE DLBCL-1 study comparing single-agent epcoritamab against chemoimmunotherapy, epcoritamab demonstrated markedly superior 36-month progression-free survival (27% versus 8%), but failed to show a statistically significant overall survival benefit for US regulatory endpoints. Dr. Elizabeth Budde noted this discrepancy was driven by trial execution during the COVID-19 pandemic, where a 37% COVID-19 infection rate and 17% mortality in the epcoritamab cohort compromised overall survival findings.
Chemotherapy-free or chemo-light bispecific antibody strategies demonstrate substantial clinical activity in elderly and unfit frontline diffuse large B-cell lymphoma patients. In the phase 2 MorningSun trial evaluating single-agent mosunetuzumab, patients had a median age of 82.5 years—including a patient aged 101. The chemo-free monotherapy produced a 59% complete response rate and a 69% 1-year progression-free survival rate, presenting a viable non-toxic upfront alternative.
Administering initial chemotherapy debulking before introducing bispecific antibodies drastically reduces the incidence of cytokine release syndrome in upfront diffuse large B-cell lymphoma. In a phase 2 trial combining glofitumab with R-CHOP, delaying glofitumab initiation until cycle 3 achieved substantial tumor debulking first. Consequently, cytokine release syndrome dropped to 10% while achieving a 90% complete response rate and 95% MRD negativity at 12 months.
Because CD20 x CD3 bispecific antibodies require CD20 target engagement, antigen downregulation or loss is a primary resistance mechanism in patients experiencing early relapse. Dr. Elizabeth Budde highlights that verifying CD20 expression via repeat biopsy is clinically mandatory prior to initiating bispecific treatment or determining post-relapse therapy, ensuring the target antigen remains present on lymphoma cells.
